β‐sitosterol for the treatment of benign prostatic hyperplasia:

Abstract

Objectives To conduct a systematic review of the eviInternational Prostate Symptom Score (IPSS), the weighted mean diCerence (WMD) against placebo was dence for the eBcacy of b-sitosterol in men with symptomatic benign prostatic hyperplasia (BPH).−4.9 IPSS points (95% confidence interval, CI,−6.3 to−3.5). The WMD for peak urinary flow rate was Methods Studies were identified through Medline@ (1966-98), EMBASE@, Phytodok, the Cochrane 3.91 mL/s (95% CI 0.91 to 6.90, four studies) and for residual volume the WMD was −28.62 mL (95% Library, bibliographies of identified trials and review articles, and contact with study authors and pharma-CI−41.42 to−15.83, four studies). b-sitosterol did not reduce prostate size. The trial using pure ceutical companies. Randomized trials were included if: men had symptomatic BPH; plant extract prepb-sitosterol-b-d-glucoside (WA184) showed no improvement in urinary flow measures. Withdrawal arations contained b-sitosterols; a control group received placebo or a pharmacological therapy; and rates for men assigned to b-sitosterol and placebo were 7.8% and 8.0% (not significant), respectively. treatment duration was Á30 days. Study characteristics, demographic information, enrolment criteria Conclusion b-sitosterol improves urological symptoms and flow measures. However, the existing studies are and outcomes were extracted. Results Four trials comprising a total of 519 men met limited by short treatment duration and lack of standardized b-sitosterol preparations. Their long-term the inclusion criteria. All were double-blind and lasted 4-26 weeks. Three studies used nonglucosidic beCectiveness, safety and ability to prevent the complications of BPH are unknown. sitosterols and one used a preparation that contained only b-sitosterol-b-d-glucoside. Compared with plaKeywords b-sitosterol therapy, plant extracts, benign prostatic hyperplasia (BPH), meta-analysis cebo, b-sitosterol improved urinary symptom scores and flow measures. For the two studies reporting the complications resulting from prostatic obstruction, has

Evaluation of the Anti-Inflammatory Capacity of Beta-Sitosterol in Rodent Assays

“…This type of research has shown a number of actions produced by BS: it was able to inhibit both vascular adhesion and intracellular adhesion molecule 1 expression in TNF-alpha-stimulated human aortic endothelial cells; in 2,4-dinitrofluorobenzene-induced mouse dermatitis, it was able to significantly reduce the clinical severity by inhibiting the infiltration of inflammatory cells, and the levels of IgE, interleukin-4, and histamine in the serum of treated mice; also, in the mouse carrageenan-induced inflammation air pouch model, it was determined that the chemical promoted a time-and dose-dependent increase of the calcium uptake in activated neutrophils, and inhibited myeloperoxidase, adenosine deaminase, interleukin-1 and the tumor necrosis factor. The mentioned effects, as well as the findings of the present report, support the suggested beneficial effects of BS for a number of diseases, which include benign prostatic hyperplasia, colon and breast cancer, atherosclerosis, and gastrointestinal ulceration (Wilt et al, 1999;Choudary and Trans, 2011;Hewing and Fisher, 2012;Tovey, 2015).…”

Phytochemical and Cytotoxic Investigations of the Heartwood of Caesalpinia Sappan Linn

“…Linoleic acid has possessed many biological activities such as anti-inflammatory, hypocholesterolemic cancer preventive, nematicide insectifuge, hepatoprotective, antihistamines, antiacne, antiarthritis, antieczemic, 5-alpha-reductase inhibitor, antiandrogenic, and anticoronary [16]. While the β-sitosterol also found the main compound in this plant has been reported the ability in the reduction of the growth and the multiplication on prostate cancer cell lines [17][18][19]. From the GC-MS analysis results, these major compounds could be responsible for the medicinal properties which support C. sappan for the treatment of BPH.…”

Benign Prostatic Hyperplasia

“…58 Trials lasted 4-26 weeks. It found that sitosterol significantly reduced the international prostate symptom score (2 RCTs, WMD − 4.9 points, − 6.3 to − 3.5).…”

“…Withdrawal rates were similar in both groups (7.8% in men taking sitosterol v 8.0% taking placebo, significance not stated). 58 …”